ARCT
Price
$11.03
Change
-$1.12 (-9.22%)
Updated
Oct 30 closing price
Capitalization
313.51M
5 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$4.03
Change
-$0.21 (-4.95%)
Updated
Oct 30 closing price
Capitalization
2.16B
4 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARCT vs RXRX

ARCT vs RXRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARCT vs. RXRX commentary
Oct 31, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Buy and RXRX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ARCT with price predictions
Oct 30, 2026

Momentum Indicator for ARCT turns positive, indicating new upward trend

ARCT saw its Momentum Indicator move above the 0 level on October 28, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 72 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for ARCT just turned positive on October 29, 2026. Looking at past instances where ARCT's MACD turned positive, the stock continued to rise in 41 of 49 cases over the following month. The odds of a continued upward trend are 84%.

Following a +8.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARCT advanced for three days, in 229 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

ARCT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

ARCT moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ARCT crossed bearishly below the 50-day moving average on October 15, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

The Aroon Indicator for ARCT entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.825) is normal, around the industry mean (3.154). P/E Ratio (-3.312) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (23.364) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. ARCT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for RXRX with price predictions
Oct 30, 2026

Aroon Indicator for RXRX shows an upward move is likely

RXRX's Aroon Indicator triggered a bullish signal on October 15, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 131 similar instances where the Aroon Indicator showed a similar pattern. In 118 of the 131 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RXRX as a result. In 84 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

The Moving Average Convergence Divergence (MACD) for RXRX just turned positive on October 28, 2026. Looking at past instances where RXRX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.

RXRX moved above its 50-day moving average on October 23, 2026 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for RXRX moved above the 200-day moving average on October 12, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +14.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where RXRX advanced for three days, in 207 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The 10-day RSI Indicator for RXRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 25 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RXRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.

RXRX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.362) is normal, around the industry mean (3.154). P/E Ratio (-4.030) is within average values for comparable stocks, (-1.071). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.299) among similar stocks. P/S Ratio (30.030) is also within normal values, averaging (439.237).

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. RXRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 84 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RXRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ARCT: Fundamental Ratings
ARCT
OUTLOOK RATING
1..100
24
VALUATION
overvalued / fair valued / undervalued
1..100
33
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
95
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARCTRXRX
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
87%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 1 day ago
85%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
84%
Aroon
ODDS (%)
Bearish Trend 1 day ago
85%
Bullish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 31, 2026
Stock price -- (ARCT: $11.03 vs. RXRX: $4.03)
Brand notoriety: ARCT and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 213% vs. RXRX: 100%
Market capitalization -- ARCT: $313.51M vs. RXRX: $2.16B
ARCT [@Biotechnology] is valued at $313.51M. RXRX’s [@Biotechnology] market capitalization is $2.16B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $141.65B. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 1 FA rating(s) are green while RXRX’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 0 green, 5 red.
According to our system of comparison, both ARCT and RXRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 6 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than ARCT.

Price Growth

ARCT (@Biotechnology) experienced а +12.09% price change this week, while RXRX (@Biotechnology) price change was +8.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was -14.01%, and the average quarterly price growth was -15.33%.

Reported Earning Dates

ARCT is expected to report earnings on Nov 05, 2026.

RXRX is expected to report earnings on Nov 04, 2026.

Industries' Descriptions

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ARCT
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with ALEC. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then ALEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
-9.22%
ALEC - ARCT
60%
Loosely correlated
-1.34%
CRSP - ARCT
51%
Loosely correlated
-5.23%
EDIT - ARCT
50%
Loosely correlated
-8.87%
AXON - ARCT
49%
Loosely correlated
-2.35%
RXRX - ARCT
46%
Loosely correlated
-4.95%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been loosely correlated with CRSP. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
-4.95%
CRSP - RXRX
65%
Loosely correlated
-5.23%
PRME - RXRX
61%
Loosely correlated
-9.92%
ABSI - RXRX
59%
Loosely correlated
-8.02%
BEAM - RXRX
57%
Loosely correlated
-5.58%
DNA - RXRX
57%
Loosely correlated
-12.01%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
DBND44.220.17
+0.37%
DoubleLine Opportunistic Core Bond ETF (DBND)
DTRE41.59N/A
N/A
First Trust Alerian Disruptive Technology Real Estate ETF (DTRE)
AVDV105.11-1.72
-1.61%
Avantis International Small Cap Value ETF (AVDV)
DBP86.48-3.49
-3.88%
Invesco DB Precious Metals Fund (DBP)
APPX6.45-1.69
-20.76%
Tradr 2X Long APP Daily ETF (APPX)